学术健康中心实施CYP2C19基因分型指导质子泵抑制剂用药
本文描述佛罗里达大学健康盖恩斯维尔医院将CYP2C19检测用于指导质子泵抑制剂(PPI)剂量的实施经验。不同CYP2C19基因型与PPI血药浓度和胃内pH变异性相关,可能影响疗效和不良反应风险。实施中通过自动警报提供剂量推荐,强调医生参与是关键,特殊人群需考虑。
要点
- CYP2C19快代谢和超快代谢者可能需要增加PPI剂量以提高疗效。
- CYP2C19中间代谢和慢代谢者可能需要降低PPI剂量以减少不良反应风险。
- 医生参与是成功实施CYP2C19指导PPI用药的关键。
核心结论
- 基于CYP2C19基因型指导PPI处方是可能改善PPI治疗获益风险比的实用方法。
研究设计与样本
- 本文为佛罗里达大学健康盖恩斯维尔医院实施CYP2C19检测指导PPI剂量的经验描述。
主要发现
- 不同CYP2C19基因型与PPI血浆浓度和胃内pH变异性相关,可能影响治疗失败或不良反应风险。
- UF健康精准医学项目基于CPIC指南前证据制定临床推荐,通过PPI处方时的自动警报提供剂量调整建议。
- 实施过程为迭代过程,关键教训包括医生参与至关重要、病历中的问题列表不可靠、需考虑特殊人群如儿科患者。
关键数值与推荐
- 对CYP2C19酶活性增加(快代谢和超快代谢)的个体增加PPI剂量以提高药物有效性。
- 对CYP2C19活性降低(中间代谢和慢代谢)的个体降低PPI剂量以减少伤害风险。
临床怎么用
- 在PPI处方时通过自动警报提供基于CYP2C19基因型的剂量推荐,以辅助临床决策。
- 实施中应重视医生参与,并注意特殊人群的用药考虑。
局限性
- 实施基于CPIC指南发布前的证据,当前已有CPIC指南可供参考。
- 病历中的问题列表不可靠,可能影响实施准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the implementation of CYP2C19 testing into clinical practice at University of Florida (UF) Health Gainesville hospital to guide proton pump inhibitor (PPI) dosing and the lessons learned from this experience. SUMMARY: Different CYP2C19 genotypes are associated with variability in PPI plasma concentrations and intragastric pH, which may contribute to the risk of treatment failure due to subtherapeutic concentrations and adverse effects (eg, infection, bone fracture, renal dysfunction) with sustained supratherapeutic concentrations. Based on evidence available prior to the availability of pertinent Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, the UF Health Precision Medicine Program (PMP) developed clinical recommendations, provided through automated alerts at the time of a PPI order, to (1) increase the PPI dose for individuals with genotypes linked to increased CYP2C19 enzyme activity (ie, rapid and ultrarapid metabolizers) to improve the likelihood of drug effectiveness and (2) decrease the dose for individuals with decreased CYP2C19 activity (ie, intermediate and poor metabolizers) to reduce the risk of harm. The CYP2C19-PPI implementation was an iterative process that taught us key implementation lessons. Most notably, physician engagement is essential, problem lists in the medical record are unreliable, and special populations (eg, pediatric patients) need to be considered. CONCLUSION: Guiding PPI prescribing based on CYP2C19 genotype is a practical approach to potentially improve the benefit-risk ratio with PPI therapy. Physician engagement is key for successful implementation. A CPIC guideline on CYP2C19 genotype-guided PPI dosing is now available, and automated alerts may be instituted to facilitate implementation.
引用
- Cicali EJ, Elchynski A, Thomas CD, et al. Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center. Am J Health Syst Pharm. 2023. PMID: 37166240. doi:10.1093/ajhp/zxad099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。